Back to Search
Start Over
LATEST COMPANY NEWS
- Source :
- United Kingdom Pharmaceuticals. September 10, 2024
- Publication Year :
- 2024
-
Abstract
- BioSpace - J&J Challenges AstraZeneca's Tagrisso With Phase III Data for Rybrevant, Lazcluze Combo - 9/9/2024 Johnson & Johnson on Sunday posted long-term follow-up data from the Phase III MARIPOSA [...]
- Subjects :
- Johnson & Johnson -- International economic relations
GSK PLC -- International economic relations
Pfizer Inc. -- International economic relations
Roche Holding (UK) Ltd. -- International economic relations
Seagen Inc. -- International economic relations
AstraZeneca PLC -- International economic relations
United States. Food and Drug Administration -- International economic relations
Association of the British Pharmaceutical Industry
European Union
Nucala (Medication)
Verzenio (Medication)
Mounjaro (Medication)
Lazcluze (Medication)
Yervoy (Medication)
Paxlovid (Medication)
Opdivo (Medication)
Rybrevant (Medication)
Breyanzi (Medication)
Tagrisso (Medication)
Care and treatment
International economic relations
Evidence-based medicine
Abaloparatide
Biotechnology industries -- International economic relations
Pharmaceutical industry -- International economic relations
Non-small cell lung cancer -- Care and treatment
Biological products industry -- International economic relations
Biotechnology industry -- International economic relations
Lung cancer, Non-small cell -- Care and treatment
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- United Kingdom Pharmaceuticals
- Publication Type :
- News
- Accession number :
- edsgcl.808336796